Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY2EXPLORE: Ianalumab with TPO-RA in Primary ITP and Evans Syndrome
NCT07421167Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, open-label trial of ianalumab in primary immune thrombocytopenia (ITP) and Evans syndrome (2 cohorts), sponsored by Novartis. Primary endpoint: Percentages of participants who are tolerable to ianalumab at 16 weeks. Started Aug 2026; status: recruiting.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)Evans syndrome
Beyond the preview
Go deeper on NCT07421167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421167.